Update on Stock Availability of Trulicity® (dulaglutide) 1.5mg
Trulicity® 1.5 mg is currently of limited availability
Eli Lilly Australia (Lilly) has been and is continuing to experience an unanticipated increase in demand of our Type 2 Diabetes (T2D) medication, Trulicity (dulaglutide). This increase is driven by the supply issues of another pharmaceutical company’s T2D medication which are published on the TGA medicine shortage database (1). Lilly’s priority in these circumstances is to ensure that Trulicity remains available for patients with T2D (2).
On 21 June 2022 Trulicity was also listed on the TGA medicine shortage database with Limited Availability expected until 31 August 2022 (2).
While stock of Trulicity 1.5 mg is still available in Australia, increased demand may lead to temporary delays, interruptions and/or shortages in stock available through wholesalers and at pharmacies.
Lilly is in frequent contact with wholesalers, and together we are closely monitoring stock levels through this period of increased demand, which remains dynamic. New shipments into Australia are anticipated weekly and replenishment of the supply chain is ongoing.
For patients with T2D:
Patients may experience delays in having their prescriptions filled. It is best to leave your prescription as early as possible with your regular pharmacy to allow your pharmacist time to order Trulicity for you and help you to get the medicines you need.
For prescribers & pharmacists :
If you have further questions about Trulicity supply, please contact the Lilly Medical Information team on 1800 454 559 /1800 4 LILLY (operating hours Monday to Friday, 9am – 5pm AEST).
Updated 1 August 2022
(1). Trulicity Approved Product Information, July 2020
(2). Australian Department of Health, Therapeutic Goods Administration, available at http://apps.tga.gov.au/Prod/msi/search?shortagetype=All, last accessed 21 June 2022